What Is Silo Pharma, Inc. (SILO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Silo Pharma, Inc. at its current price of $4.88. The composite intrinsic value is estimated at $4.83 (-0.9% average return), with 7 models flagging overvaluation risk. Model dispersion is worth noting: EROIC targets $13.52 (+177.3%), versus First Chicago at $0.25 (-94.9%). This +272.2% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About SILO?
12 of 13 models are currently active for SILO. Of these, 5 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates SILO's intrinsic value at $3.58, implying -26.6% downside from the current price. See which stocks rank higher →
How Does SILO Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, SILO ranks #97 by Quality of Company score. CirclFi's QOC score of 6.4/10 evaluates 32 fundamental signals. A score of 6.4 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Silo Pharma, Inc. competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is SILO a Value Trap?
CirclFi's Value Trap algorithm assigns SILO a score of 20/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Silo Pharma, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Silo Pharma, Inc. is rated at 6.4/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +272.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every SILO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across SILO's 12 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad